June 09, 2012

Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes

– Approximately 50 percent more patients on Lantus® achieved target HbA1c versus sitagliptin at study endpoint –
– EASIE study findings published in The Lancet –

 

Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes
– Approximately 50 percent more patients on Lantus® achieved target HbA1c versus sitagliptin at study endpoint –
– EASIE study findings published in The Lancet –

Paris, France – June 9, 2012 – Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c – glycated hemoglobin – reduction with Lantus® (insulin glargine [rDNA origin] injection) versus sitagliptin. These data from the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naïve Patients) study were presented at the American Diabetes Association 72nd Scientific Sessions. Results of the study were also published today online in The Lancet.